Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Not yet recruiting1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (33.3%)
N/A2 (66.7%)

Trials by Status

not_yet_recruiting133%
completed133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_4

RESCUE: PCSK9 Inhibitors for Carotid Vulnerable Plaque Remodeling

NCT07819643
completednot_applicable

Effects of Beta-glucan From Barley and Oats on Glucose and Lipid Metabolism, and Satiety

NCT03648112
terminatednot_applicable

OrthoPulse Gen 2 Initial Device Evaluation and Assessment of Clinical Effectiveness (CA)

NCT04386278

Clinical Trials (3)

Showing 3 of 3 trials
NCT07819643Phase 4

RESCUE: PCSK9 Inhibitors for Carotid Vulnerable Plaque Remodeling

Not Yet Recruiting
NCT03648112Not Applicable

Effects of Beta-glucan From Barley and Oats on Glucose and Lipid Metabolism, and Satiety

Completed
NCT04386278Not Applicable

OrthoPulse Gen 2 Initial Device Evaluation and Assessment of Clinical Effectiveness (CA)

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3